Literature DB >> 11587346

A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography.

J Li1, R W Milne, R L Nation, J D Turnidge, K Coulthard, D W Johnson.   

Abstract

A simple, selective and sensitive high-performance liquid chromatographic (HPLC) method is described for the determination of colistin in human plasma. Derivatization with 9-fluorenylmethyl chloroformate was performed in the same solid-phase extraction C18 cartridge used for sample pre-treatment, followed by reversed-phase HPLC with fluorimetric detection. Quantification was achieved using the ratio of the summed peak areas of colistin A and B derivatives to that of the derivative of netilmicin (internal standard). Linear calibration curves were obtained within the concentrations of colistin sulfate from 0.10 to 4.0 mg/l in plasma. Accuracy was within 10% and reproducibility (RSD) was less than 10%.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587346     DOI: 10.1016/s0378-4347(01)00326-7

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  51 in total

1.  Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Timothy C Smeaton; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard; Jason Valentine
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

3.  Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.

Authors:  Roberto Imberti; Maria Cusato; Giovanni Accetta; Valeria Marinò; Francesco Procaccio; Alfredo Del Gaudio; Giorgio A Iotti; Mario Regazzi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 4.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

5.  Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry.

Authors:  Patrice Gobin; Florian Lemaître; Sandrine Marchand; William Couet; Jean-Christophe Olivier
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

6.  Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Authors:  J Li; C R Rayner; R L Nation; R Deans; R Boots; N Widdecombe; A Douglas; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

7.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Chun-Hong Tan; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

Review 9.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.